Peptide T is an octapeptide from the V2 region of HIV-1 gp120 . Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor. In Vitro Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4. Peptide T at 10 -8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10 -9 M concentration significantly inhibits IFN-g production by PBMC. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CD4, HIV